# Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

> **NCT04195139** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Sydney** · enrollment: 103 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04195139
- **Lead sponsor:** University of Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-02-22
- **Primary completion:** 2024-06-28
- **Final completion:** 2025-12-31
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2024-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04195139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04195139, "Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT04195139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*